Next Article in Journal
Measuring Drug Therapy Effect on Osteoporotic Fracture Risk by Trabecular Bone Lacunarity: The LOTO Study
Next Article in Special Issue
Integrative Approaches in Acute Ischemic Stroke: From Symptom Recognition to Future Innovations
Previous Article in Journal
Effect of Polyunsaturated Fatty Acids on Temozolomide Drug-Sensitive and Drug-Resistant Glioblastoma Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Biomedicines
Volume 11
Issue 3
10.3390/biomedicines11030780
biomedicines-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Nanotechnology in Stroke: New Trails with Smaller Scales

by
Karlo Toljan
1,
Anushruti Ashok
2,
Vinod Labhasetwar
2,* and
M. Shazam Hussain
3,*
1
Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
2
Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA
3
Cerebrovascular Center, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44195, USA
*
Authors to whom correspondence should be addressed.
Biomedicines 2023, 11(3), 780; https://doi.org/10.3390/biomedicines11030780
Submission received: 19 January 2023 / Revised: 26 February 2023 / Accepted: 1 March 2023 / Published: 4 March 2023
(This article belongs to the Special Issue Acute Ischemic Stroke: From Imaging Diagnosis to the Latest Treatment Strategy)
Browse Figures
Versions Notes

Abstract

:
Stroke is a leading cause of death, long-term disability, and socioeconomic costs, highlighting the urgent need for effective treatment. During acute phase, intravenous administration of recombinant tissue plasminogen activator (tPA), a thrombolytic agent, and endovascular thrombectomy (EVT), a mechanical intervention to retrieve clots, are the only FDA-approved treatments to re-establish cerebral blood flow. Due to a short therapeutic time window and high potential risk of cerebral hemorrhage, a limited number of acute stroke patients benefit from tPA treatment. EVT can be performed within an extended time window, but such intervention is performed only in patients with occlusion in a larger, anatomically more proximal vasculature and is carried out at specialty centers. Regardless of the method, in case of successful recanalization, ischemia-reperfusion injury represents an additional challenge. Further, tPA disrupts the blood-brain barrier integrity and is neurotoxic, aggravating reperfusion injury. Nanoparticle-based approaches have the potential to circumvent some of the above issues and develop a thrombolytic agent that can be administered safely beyond the time window for tPA treatment. Different attributes of nanoparticles are also being explored to develop a multifunctional thrombolytic agent that, in addition to a thrombolytic agent, can contain therapeutics such as an anti-inflammatory, antioxidant, neuro/vasoprotective, or imaging agent, i.e., a theragnostic agent. The focus of this review is to highlight these advances as they relate to cerebrovascular conditions to improve clinical outcomes in stroke patients.

1. Introduction

Globally, stroke is a leading cause of death and long-term disability [1]. In the United States, it is the 5th leading cause of death, with 795,000 new cases per year [2]. The estimated cost to the healthcare system is $28 billion per year, with another $17.5 billion as an indirect cost due to lost productivity or mortality [3]. Ischemic stroke caused by arterial occlusion is responsible for the majority of strokes. Current acute ischemic stroke treatment is based on the early application of intravenous thrombolytics [4], primarily alteplase (recombinant tissue plasminogen activator, tPA), and in a selected patient population, endovascular thrombectomy (EVT) [5]. Although both modalities have enabled effective treatment of acute ischemic stroke, limitations are still present (Figure 1). These treatments were initially utilized in <5% of acute ischemic stroke cases by the early 2010s [5,6,7], but with growing evidence and updated guidelines, the theoretic eligibility for such presentations at a comprehensive stroke center increased to ~20% for EVT and ~35% for thrombolysis [8,9]. Current guidelines support the use of alteplase within a 4.5 h period since symptom onset and EVT use in the first 24 h period, based on the appropriate selection of the patient population [4].
Developing a thrombolytic agent with an extended window for stroke treatment is an unmet clinical need, and is an active area of research, with a potential benefit extending to selected cases based on salvageable penumbral tissue as determined by neuroimaging assessing perfusion or diffusion. In addition, there is a significant fraction of patients with “wake-up stroke” (patients who go to sleep but are awakened with stroke symptoms, representing roughly one in five acute ischemic strokes) [10]. Besides time as the main limiting factor for acute stroke treatment, reperfusion injury [11] and hemorrhagic complications are the most prominent life-threatening side effects once recanalizing therapies have been applied (Figure 2) [12,13]. In the subset of stroke with emergent large vessel occlusion (ELVO), tPA is less effective due to its limited contact and penetration within a large clot to cause thrombolysis and recanalization due to its short half-life (~5 min) [14,15,16].
EVT has emerged as the standard of care for patients with ELVO, but its effectiveness is also time dependent [17,18] and it must be performed by trained neurointerventionalists, requiring patients to be directed to highly specialized centers [19]. The procedure is associated with a high risk of vascular damage/perforation if not performed properly. Often, and depending on the clot composition, particularly if it is a fibrin-rich hard clot, multiple passages during EVT are required to remove the it. With each passage, there is increased risk of vascular damage [20]. In addition, thrombus fragments formed as a result of the procedure can obstruct distal and small vasculature, which may require the use of tPA [21]. In general, ELVO remains a challenge in cases of thrombolysis only, whereas application of a thrombolytic agent with successful thrombectomy has a similar risk of hemorrhagic complications as compared to thrombolysis alone (2–7%) [22,23,24].

1.1. Effect of Clot Composition on Thrombolysis

Composition, features, and location of the clot impact the effectiveness of therapies. Longer clots and clots in large vessels [25], such as a distal internal carotid artery or basilar artery, are associated with lower rates of recanalization following the use of tPA only [26,27], rather than tPA with EVT combination [28,29,30,31]. Establishing stroke etiology may discern whether occlusion occurred as a likely isolated acute process (e.g., cardioembolism) or a combination of acute and chronic processes (e.g., embolism of an atherosclerotic vessel), which also has implications regarding clot composition and expected acute treatment response [32].
Red blood cell-rich clots, suggestive of an earlier phase of thrombosis and cardioembolism as etiology, respond better to recanalizing attempts with tPA than the fibrin and platelet-rich clots [17,18]. However, after a fresh clot is formed, granulocyte infiltration is noted (lytic thrombus), followed by smooth muscle cell ingrowth (organized thrombus), implying decreased specificity of thrombus type as it ages [33]. In the acute stroke population, there is also a freshly formed component on top of any underlying subacute or chronic thrombus [34]. Platelet-rich clots, associated with large artery atherosclerosis as the etiology [34] are more resistant to tPA treatment than red blood cell-rich clots associated with cardioembolism [32] as they appear to be less permeable to thrombolytic agent [35,36,37,38].
Recently, there has been a renewed interest in the use of a 3rd generation thrombolytic, tenecteplase, which is more fibrin specific and more resistant to plasminogen activator inhibitor-1 with a longer plasma half-life [39] which may offer better recanalization rates for ELVO as compared to the currently used alteplase (half-life = 5 vs. 17 min) [40]. In addition, because of the longer half-life, tenecteplase can be administered as a single bolus injection, whereas tPA is administered first as a 10% bolus dose followed by a slow infusion over a period of 60 min [41]. The slow infusion of the second part of the dose is to sustain the effect of tPA so that there is more contact time with the clot to cause its lysis and also to reduce the risk of non-specific hemorrhage that may occur by giving the entire dose as a bolus injection [42]. Although approved for acute myocardial infarction, recent data indicate that tenecteplase is just as good as tPA, with no additional risk, and in some cases better regarding the functional outcome at 90 days, outcomes of post-thrombolytic bleeding, and recanalization/reperfusion rates following thrombectomy [43].

1.2. Reperfusion and Hemorrhagic Injury

Hemorrhagic complications remain the major concern when applying reperfusion therapies or EVT in the setting of acute ischemic stroke [44]. Overall, the risk of hemorrhage from thrombolysis with or without EVT is approximately 6%, with increased risk seen in those treated later in the therapeutic time window [45]. Larger stroke size, older age, high systolic blood pressure, or concurrent use of antiplatelets are additional major risk factors associated with hemorrhagic transformation following acute ischemic stroke treatment [45]. It is theorized that hemorrhagic risk is mainly driven by recanalization and reperfusion injury [46,47,48], though tPA itself may lead to tissue injury in areas of infarcted tissue with already compromised blood-brain barrier (BBB) integrity [49].
Acute stroke is associated with local and systemic inflammatory response [50] with activation of non-specific immunity, including neutrophils [51] and complement system [52] as well as platelets (Figure 3) [53]. Such events are associated with rapid production of reactive oxygen and nitrogen species (ROS; RNS) and secondary damaging effects encompassing mitochondria, endothelial cells, and, in case of loss of BBB integrity, even neurons and glial cells [50,54]. Consequently, there is a higher expression of endothelial adhesion molecules and leukocyte recruitment, secondary cascades producing damage-associated molecular patterns [55], and further generation of ROS and RNS as a pathophysiological vicious cycle [56].
In the case of successful reperfusion, classic features of ischemia/reperfusion (I/R) injury are present (Figure 3) [46,57]. Notably, those are represented by increased ROS and RNS formation as a non-specific inflammatory response, including the innate immune system and mitochondria. Additional oxidative cascades are mediated by xanthine oxidase as a result of functional enzyme modification due to ischemia or activation of nicotinamide adenine dinucleotide phosphate oxidase as part of oxidative stress [57,58]. Moreover, the restored circulation supplying more oxygen to the area of completed infarct or penumbral tissue, possibly already affected by considerable oxidative stress [59], may induce or worsen neuroinflammation and associated excitotoxicity, as well as vasogenic edema or cytotoxic edema [46,57] (Figure 3). Although the aforementioned pathophysiological consequences are part of the same process, an individualized timeline is present, as demonstrated by clinical scenarios in which BBB integrity may be maintained even several days from initial stroke symptom onset [60].
Thus, there is an unmet clinical need to develop a thrombolytic agent which would reduce the risk of cerebrovascular complications, particularly hemorrhagic, ideally with an extended time window for treatment. Conversely, earlier availability of such improved treatment modalities should also reduce individual risks for reperfusion injury and its consequences. The other challenge to resolve is an agent that would be effective on the clots of different compositions (red clot vs. white clot). In this regard, nanotechnology and other mechanical approaches are being investigated to overcome some of the critical issues associated with the recanalization of cerebrovascular occlusions.

2. Nanoparticles and Nanoconjugates

A novel paradigm based on nanoparticles and nanoconjugates for the delivery of therapeutics and targeting is emerging for cerebrovascular diseases. For developing effective treatment for ELVO, different approaches have been explored to minimize the damage due to I/R injury. The injury is caused by a sudden resumption of blood flow, which is further aggravated with the presence of a thrombolytic agent such as tPA due to the risk of hemorrhagic complications [61]. In recent advances, a thrombolytic agent is either encapsulated or conjugated to the nanoparticle surface to enhance its efficacy. The main objectives of these efforts are to (a) reduce the risk of hemorrhage, (b) achieve better recanalization than with the currently used thrombolytic agents, (c) protect the cerebrovascular tissue from I/R injury, and (d) extend the window for treatment (Figure 4). A safer and more effective thrombolytic agent will benefit more acute stroke patients than those treated with the currently used thrombolytic agents.

2.1. Nanoparticles

Nanoparticles are submicron-sized particles, typically in the size range of 50 to 300 nm in diameter, particularly when used for drug delivery applications. Nanoparticles are mostly spherical in shape, but they have been synthesized with different architectures [62]. Depending upon their applications, nanoparticles are formulated using different biomaterials such as synthetic or natural polymers [63], lipids (e.g., glycerides, fatty acids, fatty alcohols, etc.), or metals (e.g., gold, iron oxide, etc.) [64,65]. Polymers could be synthetic (e.g., poly lactic-co-glycolic acid, PLGA; polylactide, PLL; poly-methyl methacrylate, PMMA, etc.) or natural (e.g., gelatin, chitosan, etc.) [63]. Nanoparticles such as cyclodextrins which contain a cargo to encapsulate therapeutic agents [66] or self-assembling polymer complexes, commonly referred to as micelles, can solubilize water-insoluble therapeutics [67]. Depending upon their specific applications, nanoparticles can be surface functionalized, such as with polyethylene glycol (PEG), commonly referred to as PEGylated nanoparticles that are stealth to the immune system and hence have longer circulation time than non-PEGylated nanoparticles [68]. In addition, PEG is used for conjugating nanoparticles to a targeting ligand [69].

2.2. Nanoparticles for Stroke Therapy

Although nanoparticles have been extensively investigated for drug delivery and imaging applications in other disease conditions, particularly for cancer therapies and for improving oral bioavailability of therapeutics, and in other emerging areas such as the ophthalmic delivery, for vaccine delivery, e.g., mRNA-based COVID-19 vaccine [70], their potential for cerebrovascular conditions has not yet been fully explored [71]. Depending upon the target or the objective, the size of nanoparticles is an important consideration [72]. Very small-sized nanoparticles (<10 nm) can rapidly clear through glomerular filtration and will be excreted [73], whereas too large-sized nanoparticles could impede their transport into the clot, carrying thrombolytic agents, or their transport of neuroprotective agents to the penumbra [74]. Nanoparticles have been evaluated for delivering therapeutic agents of different types—small molecular therapeutics and macromolecules. Therapeutic agent(s) of different types or pharmacological effects can be encapsulated or conjugated/adsorbed onto the surface [64,75]. Advantages of nanoparticle-based drug-delivery systems are multiple such as sustained/controlled release of the encapsulated agent, protection of unstable therapeutics, targeting, and/or altering biodistribution to limit unwanted side-effects [76].
For this review, we refer to nanoconjugates as the formulation where the nanoparticle surface is modified. Nanoparticles, as such, can have either encapsulated therapeutics (within the polymer), conjugated (onto the surface), or have both encapsulated and conjugated. The surface can be modified with a targeting ligand. An attempt has been made to develop multifunctional nanoconjugates that would include complementary features to enable multi-target action for improved stroke therapy. With nanoparticles as a base, one could encapsulate a variety of agents that could be neuro/vascular protective and targeted toward the diseased vessel or specific component of the thrombus. Therefore, nanoparticle-based formulations that are being developed and investigated for ischemic stroke therapy are typically composed of three major components, (i) nanoparticle, (ii) thrombolytic agent such as tPA, and/or (iii) imaging agent/cerebrovascular-neuroprotective agent/targeting ligand (Figure 5). The following section will briefly discuss these components and some recent advancements in nanoconjugate-based drug-delivery systems relevant to the stroke condition.

2.2.1. Nanoparticles with Thrombolytic Agents

Nanoparticles are investigated to deliver tPA or other thrombolytics that are either encapsulated or conjugated to nanoparticles. The advantage of encapsulation is that it temporarily suppresses the tPA activity while in the blood circulation, thus extending its half-life, allowing more contact time with the clot than tPA administered as a solution, therefore achieving better thrombolysis and also minimizing the risk of non-specific bleeding, due to controlled release of tPA [77,78]. In addition, encapsulation protects the thrombolytic agent from endogenous inhibitors of fibrinolysis (e.g., α-2-antiplasmin, α-2-macroglobuline, anti-C1 esterase, α-1 antitrypsin, and plasminogen activator inhibitor 1), thus potentiating the thrombolysis effect of the encapsulated thrombolytic agent [79]. Sustained release of the encapsulated agent also reduces the potential risk of tPA-mediated hemorrhage at non-target regions [80].
Immobilization/conjugation of tPA to the nanoparticle surface through covalent attachment offers more stability than free tPA due to their fixed conformation, which permits tPA to act directly on the thrombus. In this regard, multiple different types of nanoparticles with encapsulated or conjugated tPA and other thrombolytic agents have been formulated, such as PEGylated liposomes [81], silica-coated magnetic nanoparticle (SiO2-MNP) [82], magnetic nanoparticles, [83,84], gold nanoparticles (tPA/AuNP) [85], and polymeric nano-constructs (tPA-DPNs) [86].

2.2.2. Nanoparticles with Imaging Agents

With the additional feature of imaging capability, one would be able to determine the localization of the nanoconjugate to the target vessel/thrombus, retention, and whether recanalization has occurred or not, which would help to detect/image the severity of stroke injury and determine the effective dose or dosing frequency of the nanoconjugate required for recanalization. Imaging techniques are used, including nanoparticle-based, to enable the diagnosis of cerebral vasculature pathologies, infarct region, compromised BBB integrity, and detect neuroinflammation markers [87]. Those techniques could be used in predicting complications such as massive cerebral edema and hemorrhagic transformation in the acute ischemic stroke [88].
Nanoparticles with a thrombolytic agent, but also with imaging features, have been developed and evaluated. For example, nanosized erythrocyte ghosts, which have a long circulation time, contained encapsulated indocyanine green (ICG) with tPA conjugated to the surface with fluorescence imaging and thrombolysis properties [89]. Similarly, bovine serum albumin (BSA) containing Mn and ICG as a contrast agent (MnCO3@BSA-ICG nanoconjugate) that comprises the magnetic resonance/photoacoustic (MR/PA) dual-modal imaging system has been explored to detect infarct area [90]. Biocompatible BSA–MnO2 nanoparticles [91], PEGylated superparamagnetic iron oxide nanoparticles (SPION) [92], and gadolinium (Gd)-based [93] contrast agents have been successfully synthesized for quantitative BBB permeability imaging.
Apart from a thrombolytic agent, other applications of nanoparticles are useful in stroke conditions. For example, fluorescent mesoporous silica coated SPION have been used to track neural progenitor cells migrating to the lesion site [94]. Gd-based contrast agent, (nanoGd conjugate), which can be internalized by phagocytic cells, has been explored to monitor neuroinflammation at the subacute stage of ischemic stroke [95]. Similarly, carbohydrate-functionalized core-shell silica magnetic nanoparticles which specifically bind to the endothelial transmembrane inflammatory proteins (E and P selectin) were tested to monitor post-stroke inflammation [96]. Due to the ability of mesenchymal stem cells (MSC) to migrate toward the neuro-inflammatory signal, MSC-derived exosome nanovesicles combined with gold nanoparticles were tested to analyze brain pathology in the stroke [97].

2.2.3. Nanoparticles with Cerebrovascular-Neuroprotective Agents

Nanoparticles with thrombolytic properties containing neuroprotective agents against cellular and molecular markers involved in the secondary pathological mechanisms in stroke are developed to rescue hypoperfused penumbra from cell death [98]. Considering the role of platelets during thrombus formation, bioengineered nanoplatelet conjugated with neuroprotectant (ZL006e) for targeted delivery of tPA for ischemic stroke treatment in a model study demonstrated site-specific delivery of the conjugate, reduced ischemic area, and reduced ROS levels compared with free drug combination [99]. Similarly, platelet membrane-cloaked polymeric nanoparticles with tPA (PNP-tPA) resulted in targeting and local clot degradation, with lower bleeding risk than free t-PA, improving the 20-day survival from 20% with tPA to 70% with PNP-tPA [100]. Liposomes with neuroprotectant (tacrolimus) significantly suppressed neuronal damage and ameliorated motor function deficits at one week of the middle cerebral artery occlusion (MCAO) rats [101].

2.2.4. Nanoparticles with Targeting Ligands

To improve the specificity and efficacy of the thrombolytic agent, nanoparticles are conjugated with a specific ligand targeting fibrin, activated platelets, or factor XIII, which are associated with thrombus formation [102]. Fucoidan has a strong affinity for P-selectin expressed by the activated platelets during thrombus formation, hence nanoparticles with it have been shown to result in targeted delivery by tracking the platelet density and have shown improved thrombolysis efficacy (thrombus density reductions 29.5% vs. 59% with tPA) [103]. Other examples include L-carnosine peptide conjugated magnetic nanoparticles (LMNP) loaded with dexamethasone (dm@LMNP), which showed their effective BBB crossing with the potential application in ischemic stroke [104]. Magnetic nano vesicles (MNV) derived from iron oxide nanoparticles (IONP)-harboring MSC possess the advantage of magnetic navigation, which increased the localization to the ischemic lesion by 5.1 times [105].

3. Nanoconjugates to Protect the Brain from I/R Injury

In stroke, protecting cerebral vasculature is an important target to prevent the breakdown of the BBB, which could lead to inflammatory cells migrating to the brain parenchyma, oxidative stress, and edema that can further trigger a downstream secondary reperfusion injury (Figure 3). Even if the clot is successfully resolved, reperfusion injury still entails a pro-inflammatory cascade akin to ischemic tissue changes [106]. Besides the reperfusion injury, hemorrhagic conversion of ischemic stroke represents another possible early sequela, either as a spontaneous event or after recanalizing therapy use. In such instances, subsequent pathophysiology is shared with the course of parenchymal hemorrhagic stroke. Therefore, the development of effective combination therapy for stroke that provides not only thrombolysis but also attenuates secondary I/R injury is also necessary.

3.1. Nanoparticles with Antioxidant Agents

Metal nanoparticles acting as free radical scavengers such as cerium, platinum, selenium, and gold nanoparticles have shown protective effects in animal I/R injury models by regaining redox balance and preserving mitochondrial integrity [107,108]. Experiments also included the use of a targeting ligand with cerium nanoparticles such as integrin αvβ3, which is upregulated during ischemic injury [109]. These conjugated nanoparticles demonstrated better outcomes in terms of improved neurologic impairment scores, decreased infarction volume, decreased BBB disruption, oxidative stress, and neuronal apoptosis in the MCAO rat model [110]. Additional efforts included combining cerium nanoparticles with edaravone, another antioxidant, for a synergistic effect in neutralizing ROS [111]. Natural antioxidants such as resveratrol, a polyphenol antioxidant [112] resveratrol conjugated to low-density lipoprotein receptor [113], curcumin [114], nanozyme [115], melanin nanoparticle [115], melanin nanoparticles combined with MSC [116], betulinic acid (BA) [117], and glyburide-loaded BA [118] have been produced a protective effect in various models assessing their effectiveness against I/R injury-related oxidative stress.
In our efforts to address the issue of I/R injury, we encapsulated antioxidant enzymes, either catalase (nano-CAT) or superoxide dismutase (nano-SOD) or a combination of both (nano-SOD/CAT) in biodegradable, PLGA-based nanoparticles. We tested them in vitro, both in neurons and astrocytes, for their protective effect against hydrogen peroxide-induced oxidative stress [119,120]. The subsequent studies were carried out in the MCAO rat model of I/R injury [121] and in a thromboembolic model [122]. The treatments were given via the carotid artery at the time of reperfusion. In the thromboembolic model, it was a sequential treatment, tPA, followed by nano-SOD/CAT. The advantage of using antioxidant enzymes is their catalytic mechanism of action; hence they are very effective in neutralizing ROS even at low doses [123]. The compounds with antioxidant properties are inactivated after interaction with ROS, necessitating repeated dosing to maintain their therapeutic levels, which could be challenging in a clinical setting.
Our data demonstrated the protective effect of nano-SOD and nano-CAT in neurons [119] and astrocytes [120] from oxidative stress in cell culture experiments. In the MCAO rat model, many aspects of I/R injury were inhibited following treatment with enzyme-loaded nanoparticles, which had favorable effects including protection of the BBB, inhibition of edema, reduction in infarct volume, improved neurological recovery, and long-term survival [121]. Interestingly in the embolic stroke model, tPA-only treatment was seen to inhibit the migration of progenitor cells and stem cells from the subventricular zone, but the combination treatment, i.e., tPA followed by nano-CAT/SOD, restored the above cellular activities, promoting neurogenesis [122]. In the above study, the sequential treatment of tPA followed by nano-CAT/SOD inhibited edema (Figure 6), indicating protection of BBB from I/R injury [122]. Since our initial studies, another group has shown similar efficacy with antioxidant enzyme-loaded nanoparticles [124]. Recent efforts include developing ROS-targeting nanomedicines containing an antioxidant agent to achieve target-specific delivery to the ischemic tissue [125]. Nanozyme, a polymer complex of antioxidant enzymes, has similarly shown the protective effect from I/R injury, including protecting neurons and the cerebral vasculature [126,127].

3.2. Nanoparticles with Anti-Inflammatory Agents

To overcome post-ischemic neuro-inflammatory damage, various anti-inflammatory conjugates have been studied in stroke models. For example, the liposomal cyclosporine A [128] and berberine nano micelles [129] have been reported to reduce microglial immunoreactivity, inflammatory responses, and infarct lesion volumes. Nanoparticles conjugated with monocyte membrane and rapamycin have been shown to inhibit the proliferation of neutrophils [130], reversing the pattern of inflammatory cytokines expression, resulting in improved neurological function [131]. In a few instances, the compound has pleiotropic effects. For example, bioactive nanoparticle engineered from a pharmacologically active oligosaccharide material (termed as TPCD), prepared by covalently conjugating a radical-scavenging compound (Tempol) and phenylboronic acid pinacol ester (PBAP) on β-cyclodextrin, decreased infarct volume and accelerated recovery of neurological function in the MCAO mice model, which was achieved by its simultaneous antioxidative, anti-inflammatory, and antiapoptotic effects [132].

4. Mechanical and Biological Stimulus

To loosen the clot or to improve the efficacy of thrombolytic agents, external mechanical stimuli such as ultrasound (sonothombolysis) [133,134], or external magnetic field with formulations containing magnetic nanoparticles carrying thrombolytic agents, have been explored. It is feasible to guide magnetic nanoparticles to the occlusion site using an external magnetic field to enhance the transport of tPA to the thrombus and increase the tPA-mediated thrombolysis [135,136,137]. The use of thrombus-targeting liposomal nanobubbles with concurrent high-intensity ultrasound (4.0 W/cm2) in a rabbit model of iliofemoral artery thrombosis showed recanalization in 90% of the animals as compared to 40% with tPA, or 20% with platelet non-specific nanobubbles and the same intensity of ultrasound [133]. Clinical trials with microbubbles and ultrasound increased the rate of recanalization and better outcomes in younger patients but with an increased risk of hemorrhagic complications or brain edema [138,139]. In another study, thrombus-targeting magnetic nanoparticles were developed by functionalizing iron oxide nanoparticles with an antibody recognizing activated integrin αIIbβ3. In this case, magnetic hyperthermia made the clot susceptible to the tPA-mediated thrombolysis [140].
Shear-activated nanoparticles taking the advantage of the distortion of the bloodstream caused by the clot itself, or aggregating nanoparticles releasing the tPA at the site of the stenosis, successfully recanalized blood vessels in the mouse model of embolism [141]. A similar approach has been explored by using a temporary endovascular bypass with a shear-activated nanotherapeutic that releases tPA when exposed to high levels of hemodynamic stress at sites of partial vascular occlusion in a rabbit model [142]. Anti-fibrin antibody targeting is one of the most effective methods for efficiently delivering tPA to the thrombus. Anti-fibrin antibodies deliver t-PA to the thrombus site in an inactive state, subsequently triggering its controlled activation, thereby reducing the risk of bleeding [143]. Zhang et al. have developed a self-assembling nanoformulation containing a photothermal sensitizer and a photothermal-activable nitric oxide donor. Following laser exposure, nanoformulation generated heat that facilitated its penetration into the clot and also generated nitric oxide. In animal models of acute ischemic stroke, the nanoformulation demonstrated better thrombolysis than the nanoparticle formulation without the photoactivation feature, and the produced nitric oxide prevented the recurrence of the clot formation [144].

5. Interactions at the BBB

Blood brain barrier integrity is compromised in the setting of acute stroke, but also following application of standard recanalizing therapies [145]. Mechanical thrombectomy causes local physical injury [146], while thrombolytics induce physiological changes which make the BBB more permeable [147]. Even in case of successful recanalization, I/R injury contributes to a variable degree of BBB compromise [148]. All these factors should be considered when investigating the application of nanoparticles to ameliorate some of the changes caused by ischemia as the primary event and associated secondary processes. Modifying nanoparticles by decreasing their size, maintaining a net positive charge, or by conjugating with ligands which are transcytosis transporter substrates, enhances the transport across an intact BBB [149]. By conjugation with cell-penetrating ligand, nanoparticles bypass the transcytosis pathway, while a formulation enabling a prolonged half-life further enhances the overall delivery to the target tissue, i.e., movement across BBB [149]. In the setting of acute injury which compromises the integrity of BBB, nanoparticles are able to penetrate the injured tissue site more easily [150]. The latter has been shown to occur in the setting of metabolic insults such as hypoxia [151], but experimental BBB disruption with osmotic, mechanical (ultrasound), or magnetic stimulus leading to greater NP penetrance has also been demonstrated [152]. In a clinical setting, this could be translated as therapeutic use of ultrasound to temporarily increase BBB permeability [153], while the NP-based therapy would be administered.

6. Clinical Application

Although nanotechnology is currently not approved for treatment of acute stroke or for neurorehabilitation, a considerable number of in vivo animal model studies and limited human studies offer hope and opportunities for translation into actual tools for human clinical practice (Table 1). There are multiple experiments which show how nanotechnological compounds could address stroke-associated pathophysiological processes (Table 1).
Nanoparticles with paramagnetic properties have been used as conjugates to target specific proteins in acute stroke as well as atherosclerosis. Such nanoconjugates can target intracellular or extracellular targets. Initial studies showed that smaller particles such as ultrasmall superparamagnetic iron oxide nanoparticles (USPION), with a size of less than 50 nm, have a longer half-life than larger ones, yet contrast labeling is superior with larger particles [154]. In a proof-of-concept study involving 11 subjects scheduled for carotid endarterectomy [155]. Kooi et al. reported that administration of USPION was associated with subsequent nanoparticle intake in high-risk or ruptured plaque, which was visualized with MRI and later confirmed by histopathology. In the ATHEROMA study [156], Ferumoxtran-10 as a USPION was successfully used to assess plaque status following statin use as part of the observed intervention. To boost the quality as contrast enhancers while also maximizing their additional clinical potential, micro-sized paramagnetic iron oxide nanoparticles (MPION) conjugated with antibodies aimed at receptors associated with endothelial activation, a process occurring in acute stroke, have been developed. Conjugates of such size, at the verge of nano- and microtechnology, were able to bind to activated endothelial surface proteins, e.g., vascular cell adhesion molecule-1 (VCAM-1), and act as adequately specific and sensitive contrast agents [157]. In a similar fashion, a MPION conjugate targeting P-selectin [158], or a different one targeting intercellular adhesion molecule-1 (ICAM-1) [159], were used to detect activated endothelium. This could help detect different phases of stroke, even transient ischemic attack (TIA)-related pathophysiology. Citicoline, a substance with neuroprotective effects, was combined with an immunoliposome targeting VCAM-1 [160]. It was successfully used as a theragnostic agent when the final nanoparticle reached the activated endothelium and concurrently represented a signal on chemical exchange saturation transfer (CEST) MRI. The presented capabilities would be invaluable for establishing stroke etiology, assessment of vascular inflammation and tissue at risk, or guiding further diagnostics and treatment. Moreover, nanoconjugates could also represent efficacy biomarkers when studying new or established stroke therapies.
Safety remains as a concern when considering nanoparticles for use in human subjects. Ideally, nanoconjugates should be biodegradable and non-toxic. Their profile should be favorable in terms of risks and benefits, and they indeed would represent a superior diagnostic or therapeutic modality as compared to the current standard. Targets identified in animal studies do not necessarily translate equally in the setting of the human body environment. The use of iron containing nanoparticles in acute inflammatory state may be limited by the possibility of local oxidative reaction following cellular intake. Therefore, preferred clearance could favor renal route or by enzymatic cleavage and phagocytic or endocytic mechanisms with ultimate non-toxic metabolism.
Table
Table 1. Nanoparticles and nanoconjugates investigated for potential applications in ischemic stroke diagnosis, treatment, and study of cerebrovascular pathophysiology.
Table 1. Nanoparticles and nanoconjugates investigated for potential applications in ischemic stroke diagnosis, treatment, and study of cerebrovascular pathophysiology.
Nanoparticle or Nanoconjugate UsedStudy SubjectsObjectiveReference
Ultrasmall superparamagnetic iron oxide particlesHumanDetection of high-risk or ruptured carotid artery plaque[155]
HumanAssessment of carotid plaque status following intervention (statin use)[156]
Iron oxide microparticle conjugated with specific antibodies (P-selectin, ICAM-1)MouseDetection of abnormal cerebrovascular endothelium due to transient ischemia [158]
MouseDetection of abnormal endothelium and migrating leukocytes in the setting of cerebrovascular injury (infarct, reperfusion)[159]
Iron oxide nanoparticles with an antibody recognizing activated integrin αIIbβ3Ex-vivo study (human blood clot)Improved thrombolytic binding and affinity[140]
Liposomal citicoline conjugated with VCAM-1MouseUse of conjugate as a theragnostic agent[160]
Liposomal tacrolimusRatUse as neuroprotectant to reduce inflammation[101]
Liposomal cyclosporine ARatReduction in infarct lesion size and inflammatory activity[128]
Berberine nano micellesRat[129]
PLGA-based nanoparticles with nano-catalase or superoxide dismutaseMouseDecrease in I/R injury with reduction in infarct volume, protection of the BBB integrity, and improved recovery[121]
MouseDecrease in I/R injury and amelioration of thrombolysis related decreased migration of subventricular zone stem cells[122]
Cerium, platinum, selenium, or gold nanoparticles RatImproving redox imbalance and preserving mitochondria[107]
[108]
Cerium nanoparticles with edaravone RatDecreased oxidative injury[111]
Resveratrol conjugated to LDL receptorEx vivo study (rat cell cultures)Reduction in I/R related injury[113]
Melanin loaded nanoparticlesMouse[116]
Glyburide-loaded betulinic acid nanoparticlesRat[117]
Encapsulated or conjugated tPA;
PEGylated liposomes, silica-coated or gold nanoparticles, polymeric nano-constructs		RatThrombolytic stability to enhance drug delivery to the target[81]
Mouse[82]
[85]
In vitro and mouse[86]
Nanoparticles conjugated with monocyte membrane and rapamycinRatReduction in neutrophil proliferation[130]
Lipid nanoparticle conjugated with siRNA against Toll-like receptor-4 MouseReduction in inflammation-induced microglial activation [131]
Nanoparticle TPCD (Tempol with phenyloboronic acid pinacol ester and β-cyclodextrin)MouseDecrease in infarct volume and acceleration of recovery[132]
Nanoplatelet conjugated with neuroprotectant (ZL006e)RatReduction in infarct area and improved drug delivery across BBB[99]
Platelet membrane-cloaked polymeric nanoparticles with tPAMouseImprovement of thrombolytic profile with less hemorrhagic complications[100]
MnCO3@BSA-ICG nanoconjugateMouseInfarct area detection[90]
NanoGd conjugateCynomolgus macaquesBBB permeability assessment[93]
MSC-derived exosome nanovesicles combined with gold nanoparticlesMouseTargeted delivery to injured tissue[97]
Nanoparticles with fucoidanMouseInfarct area detection, improved thrombolysis[103]
L-carnosine peptide conjugated magnetic nanoparticles loaded with dexamethasoneIn vitroDelivery of dexamethasone across BBB model[104]
Abbreviations: BBB—blood brain barrier; BSA-ICG—bovine serum albumin and indocyanine green; Gd—gadolinium; I/R—ischemia/reperfusion; ICAM-1—intercellular adhesion molecule-1; LDL—low density lipoprotein; MSC—mesenchymal stem cells; PEG—polyethylene glycol; PLGA—poly (lactic-co-glycolic acid); siRNA—small interfering ribonucleic acid; tPA—tissue plasminogen activator; VCAM—vascular cell molecule-1.

7. Concluding Remarks

Nanotechnology offers multiple opportunities, from improving thrombolysis to adding complementary features such as imaging and/or neuro/vasoprotection from inflammation and reperfusion injury. The versatility of nanotechnology, with the ability to deliver different types of therapeutics or modify the surface with targeting ligands and the ability to formulate with different materials and compositions, allows one to design and develop multifunctional nanoparticles to address different aspects of stroke diagnostics and treatment. The most critical issue at this point is extending the time window for treatment and achieving effective recanalization. Another important aspect is making the thrombolytic agent safe, which will expand its clinical use, as the technology is now underutilized due to safety concerns. It also must be recognized that most preclinical studies are carried out in otherwise healthy animals, and patients suffering from stroke may have reduced cerebrovascular reserve or reduced benefits from protective agents due to underlying pathologies or aging.

Author Contributions

All authors contributed equally to the conceptualization, methodology, writing, and editing of the manuscript. All authors have read and agreed to the published version of the manuscript.

Funding

The study described in the review from the author’s lab is funded by the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (1R01NS113680 to V.L.).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Krishnamurthi, R.V.; Ikeda, T.; Feigin, V.L. Global, Regional and Country-Specific Burden of Ischaemic Stroke, Intracerebral Haemorrhage and Subarachnoid Haemorrhage: A Systematic Analysis of the Global Burden of Disease Study 2017. Neuroepidemiology 2020, 54, 171–179. [Google Scholar] [CrossRef]
  2. Furie, K. Epidemiology and Primary Prevention of Stroke. Contin. Lifelong Learn. Neurol. 2020, 26, 260–267. [Google Scholar] [CrossRef]
  3. Virani, S.S.; Alonso, A.; Benjamin, E.J.; Bittencourt, M.S.; Callaway, C.W.; Carson, A.P.; Chamberlain, A.M.; Chang, A.R.; Cheng, S.; Delling, F.N.; et al. Heart Disease and Stroke Statistics—2020 Update: A Report from the American Heart Association. Circulation 2020, 141, e139–e596. [Google Scholar] [CrossRef]
  4. Powers, W.J.; Rabinstein, A.A.; Ackerson, T.; Adeoye, O.M.; Bambakidis, N.C.; Becker, K.; Biller, J.; Brown, M.; Demaerschalk, B.M.; Hoh, B.; et al. Guidelines for the Early Management of Patients with Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2019, 50, e344–e418. [Google Scholar] [CrossRef] [PubMed]
  5. Hassan, A.E.; Chaudhry, S.A.; Grigoryan, M.; Tekle, W.G.; Qureshi, A.I. National Trends in Utilization and Outcomes of Endovascular Treatment of Acute Ischemic Stroke Patients in the Mechanical Thrombectomy Era. Stroke 2012, 43, 3012–3017. [Google Scholar] [CrossRef] [PubMed]
  6. Katzan, I.L.; Hammer, M.D.; Hixson, E.D.; Furlan, A.J.; Abou-Chebl, A.; Nadzam, D.M. Utilization of Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke. Arch Neurol. 2004, 61, 346. [Google Scholar] [CrossRef] [PubMed]
  7. Keyhani, S.; Arling, G.; Williams, L.S.; Ross, J.S.; Ordin, D.L.; Myers, J.; Tyndall, G.; Vogel, B.; Bravata, D.M. The Use and Misuse of Thrombolytic Therapy within the Veterans Health Administration. Medical Care 2012, 50, 66–73. [Google Scholar] [CrossRef]
  8. Mokin, M.; Ansari, S.A.; McTaggart, R.A. Society of NeuroInterventional Surgery. Indications for thrombectomy in acute ischemic stroke from emergent large vessel occlusion (ELVO): Report of the SNIS Standards and Guidelines Committee. J. Neurointerv. Surg. 2019, 11, 215–220. [Google Scholar] [CrossRef] [PubMed]
  9. Vanacker, P.; Lambrou, D.; Eskandari, A.; Mosimann, P.J.; Maghraoui, A.; Michel, P. Eligibility and Predictors for Acute Revascularization Procedures in a Stroke Center. Stroke 2016, 47, 1844–1849. [Google Scholar] [CrossRef]
  10. Rubin, M.N.; Barrett, K.M. What to do With Wake-Up Stroke. Neurohospitalist 2015, 5, 161–172. [Google Scholar] [CrossRef]
  11. Marto, J.P.; Strambo, D.; Hajdu, S.D.; Eskandari, A.; Nannoni, S.; Sirimarco, G.; Bartolini, B.; Puccinelli, F.; Maeder, P.; Saliou, G.; et al. Twenty-Four–Hour Reocclusion After Successful Mechanical Thrombectomy: Associated Factors and Long-Term Prognosis. Stroke 2019, 50, 2960–2963. [Google Scholar] [CrossRef] [PubMed]
  12. Adibhatla, R.M. Integration of cytokine biology and lipid metabolism in stroke. Front. Biosci. 2008, 13, 1250. [Google Scholar] [CrossRef] [PubMed]
  13. Yaghi, S.; Willey, J.Z.; Cucchiara, B.; Goldstein, J.N.; Gonzales, N.R.; Khatri, P.; Kim, L.J.; Mayer, S.A.; Sheth, K.N.; Schwamm, L.H. Treatment and Outcome of Hemorrhagic Transformation after Intravenous Alteplase in Acute Ischemic Stroke: A Scientific Statement for Healthcare Professionals from the American Heart Association/American Stroke Association. Stroke 2017, 48, e343–e361. [Google Scholar] [CrossRef] [PubMed]
  14. Bannish, B.E.; Chernysh, I.N.; Keener, J.P.; Fogelson, A.L.; Weisel, J.W. Molecular and Physical Mechanisms of Fibrinolysis and Thrombolysis from Mathematical Modeling and Experiments. Sci. Rep. 2017, 7, 6914. [Google Scholar] [CrossRef] [PubMed]
  15. Tsivgoulis, G.; Katsanos, A.H.; Schellinger, P.D.; Köhrmann, M.; Varelas, P.; Magoufis, G.; Paciaroni, M.; Caso, V.; Alexandrov, A.W.; Gurol, E.; et al. Successful Reperfusion with Intravenous Thrombolysis Preceding Mechanical Thrombectomy in Large-Vessel Occlusions. Stroke 2018, 49, 232–235. [Google Scholar] [CrossRef]
  16. Wagstaff, A.J.; Gillis, J.C.; Goa, K.L. Alteplase: A Reappraisal of its Pharmacology and Therapeutic Use in Vascular Disorders other than Acute Myocardial Infarction. Drugs 1995, 50, 289–316. [Google Scholar] [CrossRef]
  17. Shin, J.W.; Jeong, H.S.; Kwon, H.-J.; Song, K.S.; Kim, J. High red blood cell composition in clots is associated with successful recanalization during intra-arterial thrombectomy. PLoS ONE 2018, 13, e0197492. [Google Scholar] [CrossRef]
  18. Simons, N.; Mitchell, P.; Dowling, R.; Gonzales, M.; Yan, B. Thrombus composition in acute ischemic stroke: A histopathological study of thrombus extracted by endovascular retrieval. J. Neuroradiol. 2015, 42, 86–92. [Google Scholar] [CrossRef]
  19. Saver, J.L.; Goyal, M.; van der Lugt, A.; Menon, B.K.; Majoie, C.B.L.M.; Dippel, D.W.; Campbell, B.C.; Nogueira, R.G.; Demchuk, A.M.; Tomasello, A.; et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke: A Meta-analysis. JAMA 2016, 316, 1279. [Google Scholar] [CrossRef]
  20. Mulder, M.J.H.L.; Jansen, I.G.H.; Goldhoorn, R.-J.B.; Venema, E.; Chalos, V.; Compagne, K.C.J.; Roozenbeek, B.; Lingsma, H.F.; Schonewille, W.J.; van den Wijngaard, I.R.; et al. Time to Endovascular Treatment and Outcome in Acute Ischemic Stroke: MR CLEAN Registry Results. Circulation 2018, 138, 232–240. [Google Scholar] [CrossRef]
  21. Gandhi, C.D.; Al Mufti, F.; Singh, I.P.; Abruzzo, T.; Albani, B.; Ansari, S.A.; Arthur, A.S.; Bain, M.; Baxter, B.W.; Bulsara, K.R.; et al. Neuroendovascular management of emergent large vessel occlusion: Update on the technical aspects and standards of practice by the Standards and Guidelines Committee of the Society of NeuroInterventional Surgery. J. Neurointerv. Surg. 2018, 10, 315–320. [Google Scholar] [CrossRef]
  22. Mosimann, P.J.; Kaesmacher, J.; Gautschi, D.; Bellwald, S.; Panos, L.; Piechowiak, E.; Dobrocky, T.; Zibold, F.; Mordasini, P.; El-Koussy, M.; et al. Predictors of Unexpected Early Reocclusion after Successful Mechanical Thrombectomy in Acute Ischemic Stroke Patients. Stroke 2018, 49, 2643–2651. [Google Scholar] [CrossRef] [PubMed]
  23. Sawyer, R.N. Intravenous Tissue Plasminogen Activator for Large Vessel Ischemic Stroke—Is There Still a Role? Neurosurgery 2019, 85, S34–S37. [Google Scholar] [CrossRef] [PubMed]
  24. Xian, Y.; Xu, H.; Lytle, B.; Blevins, J.; Peterson, E.D.; Hernandez, A.F.; Smith, E.E.; Saver, J.L.; Messé, S.R.; Paulsen, M.; et al. Use of Strategies to Improve Door-to-Needle Times with Tissue-Type Plasminogen Activator in Acute Ischemic Stroke in Clinical Practice: Findings from Target: Stroke. Circ. Cardiovasc. Qual. Outcomes 2017, 10, e003227. [Google Scholar] [CrossRef]
  25. Riedel, C.H.; Zimmermann, P.; Jensen-Kondering, U.; Stingele, R.; Deuschl, G.; Jansen, O. The Importance of Size: Successful Recanalization by Intravenous Thrombolysis in Acute Anterior Stroke Depends on Thrombus Length. Stroke 2011, 42, 1775–1777. [Google Scholar] [CrossRef] [PubMed]
  26. Baharoglu, M.I.; Cordonnier, C.; Salman, R.A.-S.; de Gans, K.; Koopman, M.M.; Brand, A.; Majoie, C.B.; Beenen, L.F.; Marquering, H.A.; Vermeulen, M.; et al. Platelet transfusion versus standard care after acute stroke due to spontaneous cerebral haemorrhage associated with antiplatelet therapy (PATCH): A randomised, open-label, phase 3 trial. Lancet 2016, 387, 2605–2613. [Google Scholar] [CrossRef]
  27. Bonnard, T.; Gauberti, M.; Martinez de Lizarrondo, S.; Campos, F.; Vivien, D. Recent Advances in Nanomedicine for Ischemic and Hemorrhagic Stroke. Stroke 2019, 50, 1318–1324. [Google Scholar] [CrossRef]
  28. Badhiwala, J.H.; Nassiri, F.; Alhazzani, W.; Selim, M.H.; Farrokhyar, F.; Spears, J.; Kulkarni, A.V.; Singh, S.; Alqahtani, A.; Rochwerg, B.; et al. Endovascular Thrombectomy for Acute Ischemic Stroke: A Meta-analysis. JAMA 2015, 314, 1832. [Google Scholar] [CrossRef]
  29. Bhatia, R.; Hill, M.D.; Shobha, N.; Menon, B.; Bal, S.; Kochar, P.; Watson, T.; Goyal, M.; Demchuk, A.M. Low Rates of Acute Recanalization With Intravenous Recombinant Tissue Plasminogen Activator in Ischemic Stroke: Real-World Experience and a Call for Action. Stroke 2010, 41, 2254–2258. [Google Scholar] [CrossRef]
  30. Kong, W.; Yuan, J.; Huang, J.; Song, J.; Zhao, C.; Sang, H.; Luo, W.; Xie, D.; Gao, F.; Li, H.; et al. Outcomes of Endovascular Therapy in Acute Basilar Artery Occlusion with Severe Symptoms. JAMA Netw. Open 2021, 4, e2139550. [Google Scholar] [CrossRef]
  31. Saqqur, M.; Uchino, K.; Demchuk, A.M.; Molina, C.A.; Garami, Z.; Calleja, S.; Akhtar, N.; Orouk, F.O.; Salam, A.; Shuaib, A.; et al. Site of Arterial Occlusion Identified by Transcranial Doppler Predicts the Response to Intravenous Thrombolysis for Stroke. Stroke 2007, 38, 948–954. [Google Scholar] [CrossRef] [PubMed]
  32. Tian, C.; Cao, X.; Wang, J. Recanalisation therapy in patients with acute ischaemic stroke caused by large artery occlusion: Choice of therapeutic strategy according to underlying aetiological mechanism? Stroke Vasc. Neurol. 2017, 2, 244–250. [Google Scholar] [CrossRef] [PubMed]
  33. Niesten, J.M.; van der Schaaf, I.C.; van Dam, L.; Vink, A.; Vos, J.A.; Schonewille, W.J.; de Bruin, P.C.; Mali, W.P.T.M.; Velthuis, B.K. Histopathologic Composition of Cerebral Thrombi of Acute Stroke Patients Is Correlated with Stroke Subtype and Thrombus Attenuation. PLoS ONE 2014, 9, e88882. [Google Scholar] [CrossRef]
  34. Santos, E.M.M.; Dankbaar, J.W.; Treurniet, K.M.; Horsch, A.D.; Roos, Y.B.; Kappelle, L.J.; Niessen, W.J.; Majoie, C.B.; Velthuis, B.; Marquering, H.A.; et al. Permeable Thrombi Are Associated with Higher Intravenous Recombinant Tissue-Type Plasminogen Activator Treatment Success in Patients with Acute Ischemic Stroke. Stroke 2016, 47, 2058–2065. [Google Scholar] [CrossRef] [PubMed]
  35. Brinjikji, W.; Madalina Mereuta, O.; Dai, D.; Kallmes, D.F.; Savastano, L.; Liu, Y.; Nimjee, S.M.; Nogueira, R.G.; Abbasi, M.; Kadirvel, R. Mechanisms of fibrinolysis resistance and potential targets for thrombolysis in acute ischaemic stroke: Lessons from retrieved stroke emboli. Stroke Vasc. Neurol. 2021, 6, 658–667. [Google Scholar] [CrossRef]
  36. Forlivesi, S.; Bovi, P.; Tomelleri, G.; Micheletti, N.; Carletti, M.; Moretto, G.; Cappellari, M. Stroke etiologic subtype may influence the rate of hyperdense middle cerebral artery sign disappearance after intravenous thrombolysis. J. Thromb. Thrombolysis 2017, 43, 86–90. [Google Scholar] [CrossRef] [PubMed]
  37. Molina, C.A.; Montaner, J.; Arenillas, J.F.; Ribo, M.; Rubiera, M.; Alvarez-Sabín, J. Differential Pattern of Tissue Plasminogen Activator–Induced Proximal Middle Cerebral Artery Recanalization Among Stroke Subtypes. Stroke 2004, 35, 486–490. [Google Scholar] [CrossRef]
  38. Santos, E.M.M.; Marquering, H.A.; den Blanken, M.D.; Berkhemer, O.A.; Boers, A.M.M.; Yoo, A.J.; Beenen, L.F.; Treurniet, K.M.; Wismans, C.; van Noort, K.; et al. Thrombus Permeability Is Associated With Improved Functional Outcome and Recanalization in Patients with Ischemic Stroke. Stroke 2016, 47, 732–741. [Google Scholar] [CrossRef]
  39. Davydov, L. Tenecteplase: A review. Clin. Ther. 2001, 23, 982–997. [Google Scholar] [CrossRef]
  40. Xu, N.; Chen, Z.; Zhao, C.; Xue, T.; Wu, X.; Sun, X.; Wang, Z. Different doses of tenecteplase vs alteplase in thrombolysis therapy of acute ischemic stroke: Evidence from randomized controlled trials. Drug Des. Dev. Ther. 2018, 12, 2071–2084. [Google Scholar] [CrossRef]
  41. Zitek, T.; Ataya, R.; Brea, I. Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up? West J. Emerg. Med. 2020, 21, 199–202. [Google Scholar] [CrossRef]
  42. Jilani, T.N.; Siddiqui, A.H. Tissue Plasminogen Activator; StatPearls: Treasure Island, FL, USA, 2022. [Google Scholar]
  43. Potla, N.; Ganti, L. Tenecteplase vs. alteplase for acute ischemic stroke: A systematic review. Int. J. Emerg. Med. 2022, 15, 1. [Google Scholar] [CrossRef] [PubMed]
  44. Charbonnier, G.; Bonnet, L.; Biondi, A.; Moulin, T. Intracranial Bleeding After Reperfusion Therapy in Acute Ischemic Stroke. Front. Neurol. 2021, 11, 629920. [Google Scholar] [CrossRef]
  45. Maïer, B.; Desilles, J.P.; Mazighi, M. Intracranial Hemorrhage after Reperfusion Therapies in Acute Ischemic Stroke Patients. Front. Neurol. 2020, 11, 599908. [Google Scholar] [CrossRef] [PubMed]
  46. Mandalaneni, K.; Jillella, D.V. Reperfusion Injury; StatPearls Publishing: Treasure Island, FL, USA, 2021. [Google Scholar]
  47. Spronk, E.; Sykes, G.; Falcione, S.; Munsterman, D.; Joy, T.; Kamtchum-Tatuene, J.; Jickling, G.C. Hemorrhagic Transformation in Ischemic Stroke and the Role of Inflammation. Front. Neurol. 2021, 12, 661955. [Google Scholar] [CrossRef] [PubMed]
  48. Wang, X.; Tsuji, K.; Lee, S.-R.; Ning, M.; Furie, K.L.; Buchan, A.M.; Lo, E.H. Mechanisms of Hemorrhagic Transformation after Tissue Plasminogen Activator Reperfusion Therapy for Ischemic Stroke. Stroke 2004, 35, 2726–2730. [Google Scholar] [CrossRef]
  49. Kaur, J.; Zhao, Z.; Klein, G.M.; Lo, E.H.; Buchan, A.M. The Neurotoxicity of Tissue Plasminogen Activator? J. Cereb. Blood Flow Metab. 2004, 24, 945–963. [Google Scholar] [CrossRef]
  50. Anrather, J.; Iadecola, C. Inflammation and Stroke: An Overview. Neurotherapeutics 2016, 13, 661–670. [Google Scholar] [CrossRef]
  51. Jeong, H.-G.; Cha, B.G.; Kang, D.-W.; Kim, D.Y.; Ki, S.K.; Kim, S.I.; Han, J.h.; Yang, W.; Kim, C.K.; Kim, J.; et al. Ceria Nanoparticles Synthesized with Aminocaproic Acid for the Treatment of Subarachnoid Hemorrhage. Stroke 2018, 49, 3030–3038. [Google Scholar] [CrossRef]
  52. Ma, Y.; Liu, Y.; Zhang, Z.; Yang, G.-Y. Significance of Complement System in Ischemic Stroke: A Comprehensive Review. Aging Dis. 2019, 10, 429. [Google Scholar] [CrossRef]
  53. Cevik, O.; Baykal, A.T.; Sener, A. Platelets Proteomic Profiles of Acute Ischemic Stroke Patients. PLoS ONE 2016, 11, e0158287. [Google Scholar] [CrossRef]
  54. Dogan, O.; Kisa, U.; Erdemoglu, A.K.; Kacmaz, M.; Caglayan, O.; Kurku, H. Oxidative and nitrosative stress in patients with ischemic stroke. LaboratoriumsMedizin 2018, 42, 195–200. [Google Scholar] [CrossRef]
  55. Gülke, E.; Gelderblom, M.; Magnus, T. Danger signals in stroke and their role on microglia activation after ischemia. Ther. Adv. Neurol. Disord. 2018, 11, 175628641877425. [Google Scholar] [CrossRef]
  56. Jelinek, M.; Jurajda, M.; Duris, K. Oxidative Stress in the Brain: Basic Concepts and Treatment Strategies in Stroke. Antioxidants 2021, 10, 1886. [Google Scholar] [CrossRef] [PubMed]
  57. Sun, M.-S.; Jin, H.; Sun, X.; Huang, S.; Zhang, F.-L.; Guo, Z.-N.; Yang, Y. Free Radical Damage in Ischemia-Reperfusion Injury: An Obstacle in Acute Ischemic Stroke after Revascularization Therapy. Oxidative Med. Cell. Longev. 2018, 2018, 3804979. [Google Scholar] [CrossRef] [PubMed]
  58. Granger, D.N.; Kvietys, P.R. Reperfusion injury and reactive oxygen species: The evolution of a concept. Redox Biol. 2015, 6, 524–551. [Google Scholar] [CrossRef]
  59. Gauberti, M.; De Lizarrondo, S.M.; Vivien, D. The “inflammatory penumbra” in ischemic stroke: From clinical data to experimental evidence. Eur. Stroke J. 2016, 1, 20–27. [Google Scholar] [CrossRef] [PubMed]
  60. Butler, J.; Heidari, P.; Blayney, S.; Hitomi, E.; Luby, M.; Leigh, R. Blood-brain barrier integrity of stroke patients presenting in an extended time window. BMC Neurol. 2020, 20, 54. [Google Scholar] [CrossRef]
  61. Draxler, D.F.; Lee, F.; Ho, H.; Keragala, C.B.; Medcalf, R.L.; Niego, B. t-PA Suppresses the Immune Response and Aggravates Neurological Deficit in a Murine Model of Ischemic Stroke. Front. Immunol. 2019, 10, 591. [Google Scholar] [CrossRef]
  62. Liu, Y.; Tan, J.; Thomas, A.; Ou-Yang, D.; Muzykantov, V.R. The shape of things to come: Importance of design in nanotechnology for drug delivery. Ther. Deliv. 2012, 3, 181–194. [Google Scholar] [CrossRef]
  63. Begines, B.; Ortiz, T.; Perez-Aranda, M.; Martinez, G.; Merinero, M.; Arguelles-Arias, F.; Alcudia, A. Polymeric Nanoparticles for Drug Delivery: Recent Developments and Future Prospects. Nanomaterials 2020, 10, 1403. [Google Scholar] [CrossRef]
  64. Alkaff, S.A.; Radhakrishnan, K.; Nedumaran, A.M.; Liao, P.; Czarny, B. Nanocarriers for Stroke Therapy: Advances and Obstacles in Translating Animal Studies. Int. J. Nanomed. 2020, 15, 445–464. [Google Scholar] [CrossRef]
  65. Zamanlu, M.; Eskandani, M.; Barar, J.; Jaymand, M.; Pakchin, P.S.; Farhoudi, M. Mehdi Enhanced thrombolysis using tissue plasminogen activator (tPA)-loaded PEGylated PLGA nanoparticles for ischemic stroke. J. Drug Deliv. Sci. Technol. 2019, 53, 101165. [Google Scholar] [CrossRef]
  66. Coisne, C.; Tilloy, S.; Monflier, E.; Wils, D.; Fenart, L.; Gosselet, F. Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases. Molecules 2016, 21, 1748. [Google Scholar] [CrossRef]
  67. Wu, Q.; Yan, R.; Sun, J. Probing the drug delivery strategies in ischemic stroke therapy. Drug Deliv. 2020, 27, 1644–1655. [Google Scholar] [CrossRef] [PubMed]
  68. Suk, J.S.; Xu, Q.; Kim, N.; Hanes, J.; Ensign, L.M. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. Adv. Drug Deliv. Rev. 2016, 99, 28–51. [Google Scholar] [CrossRef] [PubMed]
  69. Javia, A.; Vanza, J.; Bardoliwala, D.; Ghosh, S.; Misra, L.A.; Patel, M.; Thakkar, H. Polymer-drug conjugates: Design principles, emerging synthetic strategies and clinical overview. Int. J. Pharm. 2022, 623, 121863. [Google Scholar] [CrossRef]
  70. Mitchell, M.J.; Billingsley, M.M.; Haley, R.M.; Wechsler, M.E.; Peppas, N.A.; Langer, R. Engineering precision nanoparticles for drug delivery. Nat. Rev. Drug Discov. 2021, 20, 101–124. [Google Scholar] [CrossRef]
  71. Chen, W.; Jiang, L.; Hu, Y.; Fang, G.; Yang, B.; Li, J.; Liang, N.; Wu, L.; Hussain, Z. Nanomedicines, an emerging therapeutic regimen for treatment of ischemic cerebral stroke: A review. J. Control. Release 2021, 340, 342–360. [Google Scholar] [CrossRef] [PubMed]
  72. Albanese, A.; Tang, P.S.; Chan, W.C. The effect of nanoparticle size, shape, and surface chemistry on biological systems. Annu. Rev. Biomed. Eng. 2012, 14, 1–16. [Google Scholar] [CrossRef]
  73. Nair, A.V.; Keliher, E.J.; Core, A.B.; Brown, D.; Weissleder, R. Characterizing the interactions of organic nanoparticles with renal epithelial cells in vivo. ACS Nano 2015, 9, 3641–3653. [Google Scholar] [CrossRef]
  74. Longmire, M.; Choyke, P.L.; Kobayashi, H. Clearance properties of nano-sized particles and molecules as imaging agents: Considerations and caveats. Nanomedicine 2008, 3, 703–717. [Google Scholar] [CrossRef] [PubMed]
  75. Kumari, A.; Singla, R.; Guliani, A.; Yadav, S.K. Nanoencapsulation for drug delivery. EXCLI J. 2014, 13, 265–286. [Google Scholar] [PubMed]
  76. Panagiotou, S.; Saha, S. Therapeutic benefits of nanoparticles in stroke. Front. Neurosci. 2015, 9, 182. [Google Scholar] [CrossRef]
  77. Liu, S.; Feng, X.; Jin, R.; Li, G. Tissue plasminogen activator-based nanothrombolysis for ischemic stroke. Expert Opin. Drug Deliv. 2018, 15, 173–184. [Google Scholar] [CrossRef]
  78. Mei, T.; Kim, A.; Vong, L.B.; Marushima, A.; Puentes, S.; Matsumaru, Y.; Matsumura, A.; Nagasaki, Y. Encapsulation of tissue plasminogen activator in pH-sensitive self-assembled antioxidant nanoparticles for ischemic stroke treatment—Synergistic effect of thrombolysis and antioxidant. Biomaterials 2019, 215, 119209. [Google Scholar] [CrossRef] [PubMed]
  79. Varna, M.; Juenet, M.; Bayles, R.; Mazighi, M.; Chauvierre, C.; Letourneur, D. Nanomedicine as a strategy to fight thrombotic diseases. Future Sci. OA 2015, 1, FSO46. [Google Scholar] [CrossRef]
  80. Ma, Y.H.; Liu, C.H.; Liang, Y.; Chen, J.P.; Wu, T. Targeted Delivery of Plasminogen Activators for Thrombolytic Therapy: An Integrative Evaluation. Molecules 2019, 24, 3407. [Google Scholar] [CrossRef]
  81. Kim, J.Y.; Kim, J.K.; Park, J.S.; Byun, Y.; Kim, C.K. The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator. Biomaterials 2009, 30, 5751–5756. [Google Scholar] [CrossRef]
  82. Chen, J.P.; Yang, P.C.; Ma, Y.H.; Tu, S.J.; Lu, Y.J. Targeted delivery of tissue plasminogen activator by binding to silica-coated magnetic nanoparticle. Int. J. Nanomed. 2012, 7, 5137–5149. [Google Scholar] [CrossRef]
  83. Chen, H.A.M.; Ma, Y.H.; Hsu, T.Y.; Chen, J.P. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy. Int. J. Mol. Sci. 2020, 21, 2690. [Google Scholar] [CrossRef] [PubMed]
  84. Prilepskii, A.Y.; Fakhardo, A.F.; Drozdov, A.S.; Vinogradov, V.V.; Dudanov, I.P.; Shtil, A.A.; Bel’tyukov, P.P.; Shibeko, A.M.; Koltsova, E.M.; Nechipurenko, D.Y.; et al. Urokinase-Conjugated Magnetite Nanoparticles as a Promising Drug Delivery System for Targeted Thrombolysis: Synthesis and Preclinical Evaluation. ACS Appl. Mater. Interfaces 2018, 10, 36764–36775. [Google Scholar] [CrossRef]
  85. Tang, Z.; Li, D.; Wang, X.; Gong, H.; Luan, Y.; Liu, Z.; Brash, J.L.; Chen, H. A t-PA/nanoparticle conjugate with fully retained enzymatic activity and prolonged circulation time. J. Mater. Chem. B 2015, 3, 977–982. [Google Scholar] [CrossRef]
  86. Colasuonno, M.; Palange, A.L.; Aid, R.; Ferreira, M.; Mollica, H.; Palomba, R.; Emdin, M.; Del Sette, M.; Chauvierre, C.; Letourneur, D.; et al. Erythrocyte-Inspired Discoidal Polymeric Nanoconstructs Carrying Tissue Plasminogen Activator for the Enhanced Lysis of Blood Clots. ACS Nano 2018, 12, 12224–12237. [Google Scholar] [CrossRef] [PubMed]
  87. El-Koussy, M.; Schroth, G.; Brekenfeld, C.; Arnold, M. Imaging of acute ischemic stroke. Eur. Neurol. 2014, 72, 309–316. [Google Scholar] [CrossRef] [PubMed]
  88. Kilburg, C.; Scott McNally, J.; de Havenon, A.; Taussky, P.; Kalani, M.Y.; Park, M.S. Advanced imaging in acute ischemic stroke. Neurosurg. Focus 2017, 42, E10. [Google Scholar] [CrossRef]
  89. Vankayala, R.; Corber, S.R.; Mac, J.T.; Rao, M.P.; Shafie, M.; Anvari, B. Erythrocyte-Derived Nanoparticles as a Theranostic Agent for Near-Infrared Fluorescence Imaging and Thrombolysis of Blood Clots. Macromol. Biosci. 2018, 18, e1700379. [Google Scholar] [CrossRef] [PubMed]
  90. Song, G.; Zhang, B.; Song, L.; Li, W.; Liu, C.; Chen, L.; Liu, A. MnCO3@BSA-ICG nanoparticles as a magnetic resonance/photoacoustic dual-modal contrast agent for functional imaging of acute ischemic stroke. Biochem. Biophys. Res. Commun. 2022, 614, 125–131. [Google Scholar] [CrossRef]
  91. Hou, W.; Jiang, Y.; Xie, G.; Zhao, L.; Zhao, F.; Zhang, X.; Sun, S.K.; Yu, C.; Pan, J. Biocompatible BSA-MnO2 nanoparticles for in vivo timely permeability imaging of blood-brain barrier and prediction of hemorrhage transformation in acute ischemic stroke. Nanoscale 2021, 13, 8531–8542. [Google Scholar] [CrossRef]
  92. Liu, D.F.; Qian, C.; An, Y.L.; Chang, D.; Ju, S.H.; Teng, G.J. Magnetic resonance imaging of post-ischemic blood-brain barrier damage with PEGylated iron oxide nanoparticles. Nanoscale 2014, 6, 15161–15167. [Google Scholar] [CrossRef]
  93. Debatisse, J.; Eker, O.F.; Wateau, O.; Cho, T.H.; Wiart, M.; Ramonet, D.; Costes, N.; Merida, I.; Leon, C.; Dia, M.; et al. PET-MRI nanoparticles imaging of blood-brain barrier damage and modulation after stroke reperfusion. Brain Commun. 2020, 2, fcaa193. [Google Scholar] [CrossRef] [PubMed]
  94. Zhang, L.; Wang, Y.; Tang, Y.; Jiao, Z.; Xie, C.; Zhang, H.; Gu, P.; Wei, X.; Yang, G.Y.; Gu, H.; et al. High MRI performance fluorescent mesoporous silica-coated magnetic nanoparticles for tracking neural progenitor cells in an ischemic mouse model. Nanoscale 2013, 5, 4506–4516. [Google Scholar] [CrossRef]
  95. Hubert, V.; Hristovska, I.; Karpati, S.; Benkeder, S.; Dey, A.; Dumot, C.; Amaz, C.; Chounlamountri, N.; Watrin, C.; Comte, J.C.; et al. Multimodal Imaging with NanoGd Reveals Spatiotemporal Features of Neuroinflammation after Experimental Stroke. Adv. Sci. 2021, 8, e2101433. [Google Scholar] [CrossRef] [PubMed]
  96. Farr, T.D.; Lai, C.H.; Grunstein, D.; Orts-Gil, G.; Wang, C.C.; Boehm-Sturm, P.; Seeberger, P.H.; Harms, C. Imaging early endothelial inflammation following stroke by core shell silica superparamagnetic glyconanoparticles that target selectin. Nano Lett. 2014, 14, 2130–2134. [Google Scholar] [CrossRef]
  97. Perets, N.; Betzer, O.; Shapira, R.; Brenstein, S.; Angel, A.; Sadan, T.; Ashery, U.; Popovtzer, R.; Offen, D. Golden Exosomes Selectively Target Brain Pathologies in Neurodegenerative and Neurodevelopmental Disorders. Nano Lett. 2019, 19, 3422–3431. [Google Scholar] [CrossRef] [PubMed]
  98. Dong, X.; Gao, J.; Su, Y.; Wang, Z. Nanomedicine for Ischemic Stroke. Int. J. Mol. Sci. 2020, 21, 7600. [Google Scholar] [CrossRef]
  99. Xu, J.; Wang, X.; Yin, H.; Cao, X.; Hu, Q.; Lv, W.; Xu, Q.; Gu, Z.; Xin, H. Sequentially Site-Specific Delivery of Thrombolytics and Neuroprotectant for Enhanced Treatment of Ischemic Stroke. ACS Nano 2019, 13, 8577–8588. [Google Scholar] [CrossRef]
  100. Xu, J.; Zhang, Y.; Xu, J.; Liu, G.; Di, C.; Zhao, X.; Li, X.; Li, Y.; Pang, N.; Yang, C.; et al. Engineered Nanoplatelets for Targeted Delivery of Plasminogen Activators to Reverse Thrombus in Multiple Mouse Thrombosis Models. Adv. Mater. 2020, 32, e1905145. [Google Scholar] [CrossRef]
  101. Fukuta, T.; Ishii, T.; Asai, T.; Sato, A.; Kikuchi, T.; Shimizu, K.; Minamino, T.; Oku, N. Treatment of stroke with liposomal neuroprotective agents under cerebral ischemia conditions. Eur. J. Pharm. Biopharm. 2015, 97, 1–7. [Google Scholar] [CrossRef]
  102. Wolberg, A.S. Fibrinogen and factor XIII: Newly recognized roles in venous thrombus formation and composition. Curr. Opin. Hematol. 2018, 25, 358–364. [Google Scholar] [CrossRef]
  103. Juenet, M.; Aid-Launais, R.; Li, B.; Berger, A.; Aerts, J.; Ollivier, V.; Nicoletti, A.; Letourneur, D.; Chauvierre, C. Thrombolytic therapy based on fucoidan-functionalized polymer nanoparticles targeting P-selectin. Biomaterials 2018, 156, 204–216. [Google Scholar] [CrossRef]
  104. Lu, X.; Zhang, Y.; Wang, L.; Li, G.; Gao, J.; Wang, Y. Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment. Drug Deliv. 2021, 28, 380–389. [Google Scholar] [CrossRef]
  105. Kim, H.Y.; Kim, T.J.; Kang, L.; Kim, Y.J.; Kang, M.K.; Kim, J.; Ryu, J.H.; Hyeon, T.; Yoon, B.W.; Ko, S.B.; et al. Mesenchymal stem cell-derived magnetic extracellular nanovesicles for targeting and treatment of ischemic stroke. Biomaterials 2020, 243, 119942. [Google Scholar] [CrossRef]
  106. Choi, J.H.; Pile-Spellman, J. Reperfusion Changes after Stroke and Practical Approaches for Neuroprotection. Neuroimaging Clin. N. Am. 2018, 28, 663–682. [Google Scholar] [CrossRef] [PubMed]
  107. Kim, C.K.; Kim, T.; Choi, I.Y.; Soh, M.; Kim, D.; Kim, Y.J.; Jang, H.; Yang, H.S.; Kim, J.Y.; Park, H.K.; et al. Ceria nanoparticles that can protect against ischemic stroke. Angew. Chem. Int. Ed. Engl. 2012, 51, 11039–11043. [Google Scholar] [CrossRef] [PubMed]
  108. Amani, H.; Habibey, R.; Hajmiresmail, S.J.; Latifi, S.; Pazoki-Toroudi, H.; Akhavan, O. Antioxidant nanomaterials in advanced diagnoses and treatments of ischemia reperfusion injuries. J. Mater. Chem. B 2017, 5, 9452–9476. [Google Scholar] [CrossRef] [PubMed]
  109. Wu, X.; Reddy, D.S. Integrins as receptor targets for neurological disorders. Pharmacol. Ther. 2012, 134, 68–81. [Google Scholar] [CrossRef]
  110. Zhang, T.; Li, C.Y.; Jia, J.J.; Chi, J.S.; Zhou, D.; Li, J.Z.; Liu, X.M.; Zhang, J.; Yi, L. Combination Therapy with LXW7 and Ceria Nanoparticles Protects against Acute Cerebral Ischemia/Reperfusion Injury in Rats. Curr. Med. Sci. 2018, 38, 144–152. [Google Scholar] [CrossRef]
  111. Bao, Q.; Hu, P.; Xu, Y.; Cheng, T.; Wei, C.; Pan, L.; Shi, J. Simultaneous Blood-Brain Barrier Crossing and Protection for Stroke Treatment Based on Edaravone-Loaded Ceria Nanoparticles. ACS Nano 2018, 12, 6794–6805. [Google Scholar] [CrossRef]
  112. Lu, X.; Dong, J.; Zheng, D.; Li, X.; Ding, D.; Xu, H. Reperfusion combined with intraarterial administration of resveratrol-loaded nanoparticles improved cerebral ischemia-reperfusion injury in rats. Nanomedicine 2020, 28, 102208. [Google Scholar] [CrossRef] [PubMed]
  113. Shen, Y.; Cao, B.; Snyder, N.R.; Woeppel, K.M.; Eles, J.R.; Cui, X.T. ROS responsive resveratrol delivery from LDLR peptide conjugated PLA-coated mesoporous silica nanoparticles across the blood-brain barrier. J. Nanobiotechnol. 2018, 16, 13. [Google Scholar] [CrossRef]
  114. Marques, M.S.; Cordeiro, M.F.; Marinho, M.A.G.; Vian, C.O.; Vaz, G.R.; Alves, B.S.; Jardim, R.D.; Hort, M.A.; Dora, C.L.; Horn, A.P. Curcumin-loaded nanoemulsion improves haemorrhagic stroke recovery in wistar rats. Brain Res. 2020, 1746, 147007. [Google Scholar] [CrossRef] [PubMed]
  115. Liu, Y.; Wang, X.; Li, X.; Qiao, S.; Huang, G.; Hermann, D.M.; Doeppner, T.R.; Zeng, M.; Liu, W.; Xu, G.; et al. A Co-Doped Fe3O4 Nanozyme Shows Enhanced Reactive Oxygen and Nitrogen Species Scavenging Activity and Ameliorates the Deleterious Effects of Ischemic Stroke. ACS Appl. Mater. Interfaces 2021, 13, 46213–46224. [Google Scholar] [CrossRef] [PubMed]
  116. Tang, C.; Luo, J.; Yan, X.; Huang, Q.; Huang, Z.; Luo, Q.; Lan, Y.; Chen, D.; Zhang, B.; Chen, M.; et al. Melanin nanoparticles enhance the neuroprotection of mesenchymal stem cells against hypoxic-ischemic injury by inhibiting apoptosis and upregulating antioxidant defense. Cell Biol. Int. 2022, 46, 933–946. [Google Scholar] [CrossRef] [PubMed]
  117. Zhang, S.; Peng, B.; Chen, Z.; Yu, J.; Deng, G.; Bao, Y.; Ma, C.; Du, F.; Sheu, W.C.; Kimberly, W.T.; et al. Brain-targeting, acid-responsive antioxidant nanoparticles for stroke treatment and drug delivery. Bioact. Mater. 2022, 16, 57–65. [Google Scholar] [CrossRef]
  118. Deng, G.; Ma, C.; Zhao, H.; Zhang, S.; Liu, J.; Liu, F.; Chen, Z.; Chen, A.T.; Yang, X.; Avery, J.; et al. Anti-edema and antioxidant combination therapy for ischemic stroke via glyburide-loaded betulinic acid nanoparticles. Theranostics 2019, 9, 6991–7002. [Google Scholar] [CrossRef]
  119. Reddy, M.K.; Wu, L.; Kou, W.; Ghorpade, A.; Labhasetwar, V. Superoxide dismutase-loaded PLGA nanoparticles protect cultured human neurons under oxidative stress. Appl. Biochem. Biotechnol. 2008, 151, 565–577. [Google Scholar] [CrossRef] [PubMed]
  120. Singhal, A.M.; Morris, V.B.; Labhasetwar, V.; Ghorpade, A. Nanoparticle-mediated catalase delivery protects human neurons from oxidative stress. Cell Death Dis. 2013, 4, e903. [Google Scholar] [CrossRef]
  121. Reddy, M.K.; Labhasetwar, V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: An effective strategy to reduce ischemia-reperfusion injury. FASEB J. 2009, 23, 1384–1395. [Google Scholar] [CrossRef]
  122. Petro, M.; Jaffer, H.; Yang, J.; Kabu, S.; Morris, V.B.; Labhasetwar, V. Tissue plasminogen activator followed by antioxidant-loaded nanoparticle delivery promotes activation/mobilization of progenitor cells in infarcted rat brain. Biomaterials 2016, 81, 169–180. [Google Scholar] [CrossRef]
  123. Ashok, A.; Andrabi, S.S.; Mansoor, S.; Kuang, Y.; Kwon, B.K.; Labhasetwar, V. Antioxidant Therapy in Oxidative Stress-Induced Neurodegenerative Diseases: Role of Nanoparticle-Based Drug Delivery Systems in Clinical Translation. Antioxidants 2022, 11, 408. [Google Scholar] [CrossRef]
  124. Yun, X.; Maximov, V.D.; Yu, J.; Zhu, H.; Vertegel, A.A.; Kindy, M.S. Nanoparticles for targeted delivery of antioxidant enzymes to the brain after cerebral ischemia and reperfusion injury. J. Cereb. Blood Flow Metab. 2013, 33, 583–592. [Google Scholar] [CrossRef] [PubMed]
  125. Chen, W.; Li, D. Reactive Oxygen Species (ROS)-Responsive Nanomedicine for Solving Ischemia-Reperfusion Injury. Front. Chem. 2020, 8, 732. [Google Scholar] [CrossRef] [PubMed]
  126. Jiang, Y.; Brynskikh, A.M.; S-Manickam, D.; Kabanov, A.V. SOD1 nanozyme salvages ischemic brain by locally protecting cerebral vasculature. J. Control. Release 2015, 213, 36–44. [Google Scholar] [CrossRef] [PubMed]
  127. Manickam, D.S.; Brynskikh, A.M.; Kopanic, J.L.; Sorgen, P.L.; Klyachko, N.L.; Batrakova, E.V.; Bronich, T.K.; Kabanov, A.V. Well-defined cross-linked antioxidant nanozymes for treatment of ischemic brain injury. J. Control. Release 2012, 162, 636–645. [Google Scholar] [CrossRef]
  128. Partoazar, A.; Nasoohi, S.; Rezayat, S.M.; Gilani, K.; Mehr, S.E.; Amani, A.; Rahimi, N.; Dehpour, A.R. Nanoliposome containing cyclosporine A reduced neuroinflammation responses and improved neurological activities in cerebral ischemia/reperfusion in rat. Fundam. Clin. Pharmacol. 2017, 31, 185–193. [Google Scholar] [CrossRef]
  129. Azadi, R.; Mousavi, S.E.; Kazemi, N.M.; Yousefi-Manesh, H.; Rezayat, S.M.; Jaafari, M.R. Anti-inflammatory efficacy of Berberine Nanomicelle for improvement of cerebral ischemia: Formulation, characterization and evaluation in bilateral common carotid artery occlusion rat model. BMC Pharmacol. Toxicol. 2021, 22, 54. [Google Scholar] [CrossRef]
  130. Wang, Y.; Wang, Y.; Li, S.; Cui, Y.; Liang, X.; Shan, J.; Gu, W.; Qiu, J.; Li, Y.; Wang, G. Functionalized nanoparticles with monocyte membranes and rapamycin achieve synergistic chemoimmunotherapy for reperfusion-induced injury in ischemic stroke. J. Nanobiotechnol. 2021, 19, 331. [Google Scholar] [CrossRef]
  131. Ganbold, T.; Bao, Q.; Xiao, H.; Zurgaanjin, D.; Liu, C.; Han, S.; Hasi, A.; Baigude, H. Peptidomimetic Lipid-Nanoparticle-Mediated Knockdown of TLR4 in CNS Protects against Cerebral Ischemia/Reperfusion Injury in Mice. Nanomaterials 2022, 12, 2072. [Google Scholar] [CrossRef]
  132. Yuan, J.; Li, L.; Yang, Q.; Ran, H.; Wang, J.; Hu, K.; Pu, W.; Huang, J.; Wen, L.; Zhou, L.; et al. Targeted Treatment of Ischemic Stroke by Bioactive Nanoparticle-Derived Reactive Oxygen Species Responsive and Inflammation-Resolving Nanotherapies. ACS Nano 2021, 15, 16076–16094. [Google Scholar] [CrossRef]
  133. Hagisawa, K.; Nishioka, T.; Suzuki, R.; Maruyama, K.; Takase, B.; Ishihara, M.; Kurita, A.; Yoshimoto, N.; Nishida, Y.; Iida, K.; et al. Thrombus-targeted perfluorocarbon-containing liposomal bubbles for enhancement of ultrasonic thrombolysis: In vitro and in vivo study. J. Thromb. Haemost. 2013, 11, 1565–1573. [Google Scholar] [CrossRef] [PubMed]
  134. Uesugi, Y.; Kawata, H.; Jo, J.-I.; Saito, Y.; Tabata, Y. An ultrasound-responsive nano delivery system of tissue-type plasminogen activator for thrombolytic therapy. J. Control. Release 2010, 147, 269–277. [Google Scholar] [CrossRef]
  135. Cheng, R.; Huang, W.; Huang, L.; Yang, B.; Mao, L.; Jin, K.; ZhuGe, Q.; Zhao, Y. Acceleration of tissue plasminogen activator-mediated thrombolysis by magnetically powered nanomotors. ACS Nano 2014, 8, 7746–7754. [Google Scholar] [CrossRef]
  136. Friedrich, R.P.; Zaloga, J.; Schreiber, E.; Toth, I.Y.; Tombacz, E.; Lyer, S.; Alexiou, C. Tissue Plasminogen Activator Binding to Superparamagnetic Iron Oxide Nanoparticle-Covalent Versus Adsorptive Approach. Nanoscale Res. Lett. 2016, 11, 297. [Google Scholar] [CrossRef] [PubMed]
  137. Wang, S.; Guo, X.; Xiu, W.; Liu, Y.; Ren, L.; Xiao, H.; Yang, F.; Gao, Y.; Xu, C.; Wang, L. Accelerating thrombolysis using a precision and clot-penetrating drug delivery strategy by nanoparticle-shelled microbubbles. Sci. Adv. 2020, 6, eaaz8204. [Google Scholar] [CrossRef] [PubMed]
  138. Aureva Transcranial Ultrasound Device with tPA in Patients with Acute Ischemic Stroke (TRUST)—NCT03519737. Available online: https://clinicaltrials.gov/ct2/show/NCT03519737 (accessed on 1 February 2023).
  139. Zafar, M.; Memon, R.S.; Mussa, M.; Merchant, R.; Khurshid, A.; Khosa, F. Does the administration of sonothrombolysis along with tissue plasminogen activator improve outcomes in acute ischemic stroke? A systematic review and meta-analysis. J. Thromb. Thrombolysis 2019, 48, 203–208. [Google Scholar] [CrossRef]
  140. Cabrera, D.; Eizadi Sharifabad, M.; Ranjbar, J.A.; Telling, N.D.; Harper, A.G.S. Clot-targeted magnetic hyperthermia permeabilizes blood clots to make them more susceptible to thrombolysis. J. Thromb. Haemost. 2022, 20, 2556–2570. [Google Scholar] [CrossRef]
  141. Korin, N.; Kanapathipillai, M.; Matthews, B.D.; Crescente, M.; Brill, A.; Mammoto, T.; Ghosh, K.; Jurek, S.; Bencherif, S.A.; Bhatta, D.; et al. Shear-Activated Nanotherapeutics for Drug Targeting to Obstructed Blood Vessels. Science 2012, 337, 738–742. [Google Scholar] [CrossRef]
  142. Marosfoi, M.G.; Korin, N.; Gounis, M.J.; Uzun, O.; Vedantham, S.; Langan, E.T.; Papa, A.L.; Brooks, O.W.; Johnson, C.; Puri, A.S.; et al. Shear-Activated Nanoparticle Aggregates Combined with Temporary Endovascular Bypass to Treat Large Vessel Occlusion. Stroke 2015, 46, 3507–3513. [Google Scholar] [CrossRef]
  143. El-Sherbiny, I.M.; Elkholi, I.E.; Yacoub, M.H. Tissue plasminogen activator-based clot busting: Controlled delivery approaches. Glob. Cardiol. Sci. Pract. 2014, 2014, 336–349. [Google Scholar] [CrossRef]
  144. Zhang, H.; Zhao, Z.; Sun, S.; Zhang, S.; Wang, Y.; Zhang, X.; Sun, J.; He, Z.; Zhang, S.; Luo, C. Molecularly self-fueled nano-penetrator for nonpharmaceutical treatment of thrombosis and ischemic stroke. Nat. Commun. 2023, 14, 255. [Google Scholar] [CrossRef]
  145. Okada, T.; Suzuki, H.; Travis, Z.D.; Zhang, J.H. The Stroke-Induced Blood-Brain Barrier Disruption: Current Progress of Inspection Technique, Mechanism, and Therapeutic Target. Curr. Neuropharmacol. 2020, 18, 1187–1212. [Google Scholar] [CrossRef]
  146. Luby, M.; Hsia, A.W.; Nadareishvili, Z.; Cullison, K.; Pednekar, N.; Adil, M.M.; Latour, L.L. Frequency of Blood-Brain Barrier Disruption Post-Endovascular Therapy and Multiple Thrombectomy Passes in Acute Ischemic Stroke Patients. Stroke 2019, 50, 2241–2244. [Google Scholar] [CrossRef] [PubMed]
  147. Suzuki, Y.; Nagai, N.; Umemura, K. A Review of the Mechanisms of Blood-Brain Barrier Permeability by Tissue-Type Plasminogen Activator Treatment for Cerebral Ischemia. Front. Cell. Neurosci. 2016, 10, 2. [Google Scholar] [CrossRef] [PubMed]
  148. Bernardo-Castro, S.; Sousa, J.A.; Bras, A.; Cecilia, C.; Rodrigues, B.; Almendra, L.; Machado, C.; Santo, G.; Silva, F.; Ferreira, L.; et al. Pathophysiology of Blood-Brain Barrier Permeability Throughout the Different Stages of Ischemic Stroke and Its Implication on Hemorrhagic Transformation and Recovery. Front. Neurol. 2020, 11, 594672. [Google Scholar] [CrossRef] [PubMed]
  149. Cena, V.; Jativa, P. Nanoparticle crossing of blood-brain barrier: A road to new therapeutic approaches to central nervous system diseases. Nanomedicine 2018, 13, 1513–1516. [Google Scholar] [CrossRef] [PubMed]
  150. Smith, N.M.; Gachulincova, I.; Ho, D.; Bailey, C.; Bartlett, C.A.; Norret, M.; Murphy, J.; Buckley, A.; Rigby, P.J.; House, M.J.; et al. An Unexpected Transient Breakdown of the Blood Brain Barrier Triggers Passage of Large Intravenously Administered Nanoparticles. Sci. Rep. 2016, 6, 22595. [Google Scholar] [CrossRef] [PubMed]
  151. Sokolova, V.; Mekky, G.; van der Meer, S.B.; Seeds, M.C.; Atala, A.J.; Epple, M. Transport of ultrasmall gold nanoparticles (2 nm) across the blood-brain barrier in a six-cell brain spheroid model. Sci. Rep. 2020, 10, 18033. [Google Scholar] [CrossRef]
  152. Xie, J.; Shen, Z.; Anraku, Y.; Kataoka, K.; Chen, X. Nanomaterial-based blood-brain-barrier (BBB) crossing strategies. Biomaterials 2019, 224, 119491. [Google Scholar] [CrossRef]
  153. Carpentier, A.; Canney, M.; Vignot, A.; Reina, V.; Beccaria, K.; Horodyckid, C.; Karachi, C.; Leclercq, D.; Lafon, C.; Chapelon, J.Y.; et al. Clinical trial of blood-brain barrier disruption by pulsed ultrasound. Sci. Transl. Med. 2016, 8, 343re342. [Google Scholar] [CrossRef]
  154. Delli Castelli, D.; Gianolio, E.; Geninatti Crich, S.; Terreno, E.; Aime, S. Metal containing nanosized systems for MR-Molecular Imaging applications. Coord. Chem. Rev. 2008, 252, 2424–2443. [Google Scholar] [CrossRef]
  155. Kooi, M.E.; Cappendijk, V.C.; Cleutjens, K.B.; Kessels, A.G.; Kitslaar, P.J.; Borgers, M.; Frederik, P.M.; Daemen, M.J.; van Engelshoven, J.M. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 2003, 107, 2453–2458. [Google Scholar] [CrossRef] [PubMed]
  156. Tang, T.Y.; Howarth, S.P.; Miller, S.R.; Graves, M.J.; Patterson, A.J.; JM, U.K.-I.; Li, Z.Y.; Walsh, S.R.; Brown, A.P.; Kirkpatrick, P.J.; et al. The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J. Am. Coll. Cardiol. 2009, 53, 2039–2050. [Google Scholar] [CrossRef]
  157. Gauberti, M.; Fournier, A.P.; Docagne, F.; Vivien, D.; Martinez de Lizarrondo, S. Molecular Magnetic Resonance Imaging of Endothelial Activation in the Central Nervous System. Theranostics 2018, 8, 1195–1212. [Google Scholar] [CrossRef] [PubMed]
  158. Quenault, A.; Martinez de Lizarrondo, S.; Etard, O.; Gauberti, M.; Orset, C.; Haelewyn, B.; Segal, H.C.; Rothwell, P.M.; Vivien, D.; Touzé, E.; et al. Molecular magnetic resonance imaging discloses endothelial activation after transient ischaemic attack. Brain 2017, 140, 146–157. [Google Scholar] [CrossRef] [PubMed]
  159. Deddens, L.H.; van Tilborg, G.A.F.; van der Marel, K.; Hunt, H.; van der Toorn, A.; Viergever, M.A.; de Vries, H.E.; Dijkhuizen, R.M. In Vivo Molecular MRI of ICAM-1 Expression on Endothelium and Leukocytes from Subacute to Chronic Stages after Experimental Stroke. Transl. Stroke Res. 2017, 8, 440–448. [Google Scholar] [CrossRef]
  160. Liu, H.; Jablonska, A.; Li, Y.; Cao, S.; Liu, D.; Chen, H.; Van Zijl, P.C.; Bulte, J.W.M.; Janowski, M.; Walczak, P.; et al. Label-free CEST MRI Detection of Citicoline-Liposome Drug Delivery in Ischemic Stroke. Theranostics 2016, 6, 1588–1600. [Google Scholar] [CrossRef] [PubMed]
Biomedicines 11 00780 g001 550
Figure 1. Current acute ischemic stroke specific therapies and challenges associated with each modality. In addition to limited eligibility for acute ischemic stroke treatments, specific challenges exist in case of thrombolysis or thrombectomy, respectively. ELVO—emergent large vessel occlusion; EVT—endovascular thrombectomy.
Figure 1. Current acute ischemic stroke specific therapies and challenges associated with each modality. In addition to limited eligibility for acute ischemic stroke treatments, specific challenges exist in case of thrombolysis or thrombectomy, respectively. ELVO—emergent large vessel occlusion; EVT—endovascular thrombectomy.
Biomedicines 11 00780 g001
Biomedicines 11 00780 g002 550
Figure 2. Major challenges of current acute ischemic stroke recanalizing treatments; incomplete recanalization and hemorrhagic complications. Yellow arrow respectively points to the site of vessel occlusion (a), incompletely recanalized vessel during intervention (b), and hemorrhagic transformation of the initial ischemic infarct territory (c).
Figure 2. Major challenges of current acute ischemic stroke recanalizing treatments; incomplete recanalization and hemorrhagic complications. Yellow arrow respectively points to the site of vessel occlusion (a), incompletely recanalized vessel during intervention (b), and hemorrhagic transformation of the initial ischemic infarct territory (c).
Biomedicines 11 00780 g002
Biomedicines 11 00780 g003 550
Figure 3. Schematic depicting acute changes with reperfusion following successful vessel recanalization (on the left) contrasted with ischemia following vessel occlusion (on the right). Despite vessel recanalization, there may still be disruption in the function or structure of BBB or ischemic changes, compounded by neuroinflammatory cascades triggered by reperfusion or direct effects of thrombolytics. Nanoparticles and nanoconjugates (green dots) may help target detrimental pathophysiological changes in reperfusion and ischemia by delivery of neuroprotective and vasoprotective agents to minimize vessel injury, or by ameliorating ischemia-triggered cascades, and neuroinflammation. Theragnostics hold the potential to improve diagnostic and prognostic tools and bolster current acute treatments. BBB—blood-brain barrier, I/R—ischemia/reperfusion.
Figure 3. Schematic depicting acute changes with reperfusion following successful vessel recanalization (on the left) contrasted with ischemia following vessel occlusion (on the right). Despite vessel recanalization, there may still be disruption in the function or structure of BBB or ischemic changes, compounded by neuroinflammatory cascades triggered by reperfusion or direct effects of thrombolytics. Nanoparticles and nanoconjugates (green dots) may help target detrimental pathophysiological changes in reperfusion and ischemia by delivery of neuroprotective and vasoprotective agents to minimize vessel injury, or by ameliorating ischemia-triggered cascades, and neuroinflammation. Theragnostics hold the potential to improve diagnostic and prognostic tools and bolster current acute treatments. BBB—blood-brain barrier, I/R—ischemia/reperfusion.
Biomedicines 11 00780 g003
Biomedicines 11 00780 g004 550
Figure 4. Main objectives for clinical application of nanoparticles in acute ischemic stroke. Nanoparticle-based approaches could improve acute ischemic stroke treatment by: expanding the treatment window eligibility (safer thrombolytics) (a), improving delivery modes for thrombolytics (increased affinity for thrombus, longer half-life) and enabling delivery of neuro/vaso-protective agents (b), enhancing recanalization rates with pharmacological, physical, or chemical function (c), and reducing ischemia/reperfusion (I/R) injury with subsequent decrease in infarct site complications (hemorrhagic transformation, tissue edema) (d).
Figure 4. Main objectives for clinical application of nanoparticles in acute ischemic stroke. Nanoparticle-based approaches could improve acute ischemic stroke treatment by: expanding the treatment window eligibility (safer thrombolytics) (a), improving delivery modes for thrombolytics (increased affinity for thrombus, longer half-life) and enabling delivery of neuro/vaso-protective agents (b), enhancing recanalization rates with pharmacological, physical, or chemical function (c), and reducing ischemia/reperfusion (I/R) injury with subsequent decrease in infarct site complications (hemorrhagic transformation, tissue edema) (d).
Biomedicines 11 00780 g004
Biomedicines 11 00780 g005 550
Figure 5. Nanoparticle-based formulations as tools in stroke diagnosis and treatment. Nanoparticle-based formulations have multiple potential applications for clinical management of acute ischemic stroke including delivery of thrombolytics and neuro/vaso-protective agents, improvement of imaging capabilities, and more precise targeting, which should enhance the safety profile of acute treatments. Key components of such formulations are nanoparticles (a), combined with either thrombolytics (b) and/or imaging or targeting ligands (c), or other components such as pharmacologically active compounds (d), which could decrease tissue injury and enhance recovery.
Figure 5. Nanoparticle-based formulations as tools in stroke diagnosis and treatment. Nanoparticle-based formulations have multiple potential applications for clinical management of acute ischemic stroke including delivery of thrombolytics and neuro/vaso-protective agents, improvement of imaging capabilities, and more precise targeting, which should enhance the safety profile of acute treatments. Key components of such formulations are nanoparticles (a), combined with either thrombolytics (b) and/or imaging or targeting ligands (c), or other components such as pharmacologically active compounds (d), which could decrease tissue injury and enhance recovery.
Biomedicines 11 00780 g005
Biomedicines 11 00780 g006 550
Figure 6. Immunohistochemical analysis of brain sections for hippocampus swelling. Following thromboembolic stroke, animals received different treatments at 3 h, and brains were collected at 48 h post-stroke. Brain sections were stained for GFAP. (A) Animals treated with tPA + nano-CAT/SOD show reduced swelling in the hippocampus than untreated and tPA alone treated animals. (B) Ratio of the ipsilateral to contralateral hippocampal areas showed reduced hippocampal swelling in tPA + CAT/SOD treated than in other groups. Data as mean ± s.e.m, naïve = 2, other groups = 3 animals in each group. p = 0.06 for untreated vs. tPA + nano-CAT/SOD treated; p = 0.13 for tPA alone vs. tPA + nano-CAT/SOD treated. Reproduced with permission from [122], copyright 2016 Elsevier.
Figure 6. Immunohistochemical analysis of brain sections for hippocampus swelling. Following thromboembolic stroke, animals received different treatments at 3 h, and brains were collected at 48 h post-stroke. Brain sections were stained for GFAP. (A) Animals treated with tPA + nano-CAT/SOD show reduced swelling in the hippocampus than untreated and tPA alone treated animals. (B) Ratio of the ipsilateral to contralateral hippocampal areas showed reduced hippocampal swelling in tPA + CAT/SOD treated than in other groups. Data as mean ± s.e.m, naïve = 2, other groups = 3 animals in each group. p = 0.06 for untreated vs. tPA + nano-CAT/SOD treated; p = 0.13 for tPA alone vs. tPA + nano-CAT/SOD treated. Reproduced with permission from [122], copyright 2016 Elsevier.
Biomedicines 11 00780 g006
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Toljan, K.; Ashok, A.; Labhasetwar, V.; Hussain, M.S. Nanotechnology in Stroke: New Trails with Smaller Scales. Biomedicines 2023, 11, 780. https://doi.org/10.3390/biomedicines11030780

AMA Style

Toljan K, Ashok A, Labhasetwar V, Hussain MS. Nanotechnology in Stroke: New Trails with Smaller Scales. Biomedicines. 2023; 11(3):780. https://doi.org/10.3390/biomedicines11030780

Chicago/Turabian Style

Toljan, Karlo, Anushruti Ashok, Vinod Labhasetwar, and M. Shazam Hussain. 2023. "Nanotechnology in Stroke: New Trails with Smaller Scales" Biomedicines 11, no. 3: 780. https://doi.org/10.3390/biomedicines11030780

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop